Larimar Therapeutics News

Positive Outlook on Larimar Therapeutics' Nomlabofusp for Friedreich's Ataxia: Analyst Recommends Buy Rating

TipRanksDec 6 10:45 ET · Ratings

JMP Securities Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $21

Moomoo NewsDec 5 12:35 ET · Ratings

Express News | Larimar Therapeutics Shares Hit Session Low With Volume Pickup, Last Down 5.3% at $6.04

ReutersNov 20 15:40 ET

Larimar Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow JonesNov 18 12:54 ET · Ratings

Larimar Therapeutics Presents Additional Data From Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

GlobeNewswireNov 18 07:00 ET

Is Larimar Therapeutics (LRMR) the Best Multibagger Stock to Buy Heading Into 2025?

Yahoo FinanceNov 16 01:34 ET

Express News | Watching Larimar Therapeutics; Traders Circulate Stock Picked By Zacks Under $10 Newsletter

BenzingaNov 7 10:57 ET

Oppenheimer Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $26

Moomoo NewsNov 1 08:31 ET · Ratings

Express News | Larimar Therapeutics Inc : Guggenheim Raises Target Price to $26 From $25

ReutersOct 31 07:09 ET

Larimar Therapeutics Analyst Ratings

BenzingaOct 31 05:40 ET · Ratings

Citi Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $14

Moomoo NewsOct 30 22:33 ET · Ratings

Larimar Therapeutics | 10-Q: Q3 2024 Earnings Report

SECOct 30 17:07 ET · Announcements

H.C. Wainwright Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $15

Moomoo NewsOct 30 12:31 ET · Ratings

LifeSci Capital Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $36

Moomoo NewsOct 30 12:31 ET · Ratings

Larimar Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPS Results.

BenzingaOct 30 11:34 ET

Larimar Therapeutics GAAP EPS of -$0.24 Beats by $0.14

Seeking AlphaOct 30 07:50 ET

Larimar Therapeutics Sees Projected Cash Runway Into 2026 >LRMR

Dow JonesOct 30 07:17 ET

Larimar Therapeutics: Initiation of Global Confirmatory/registration Study Planned Mid-2025 >LRMR

Dow JonesOct 30 07:17 ET

Larimar Therapeutics: Initiation of PK Run-In Study in Adolescents on Track by Yr-end 2024 >LRMR

Dow JonesOct 30 07:17 ET

Larimar Therapeutics: Nomlabofusp Program Update Expected Mid-Dec to Include Available Safety, Pharmacokinetic and Frataxin Data >LRMR

Dow JonesOct 30 07:16 ET